Document is current
Any future updates will be listed below
-
Authors
Sidana, Surbhi https://orcid.org/0000-0003-3288-7614
Hosoya, Hitomi
Jensen, Alexandria https://orcid.org/0000-0001-6337-9079
Liu, Lawrence https://orcid.org/0000-0001-8559-7739
Goyal, Anmol
Hovanky, Vanna
Sahaf, Bita
Bharadwaj, Sushma
Latchford, Theresa
Arai, Sally
Leahy, Sheryl
Mei, Matthew https://orcid.org/0000-0002-1109-6955
Budde, Lihua E.
Muffly, Lori S.
Frank, Matthew J.
Dahiya, Saurabh
Htut, Myo
Miklos, David https://orcid.org/0000-0003-0717-4305
Janakiram, Murali
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (KL2 TR003143)
American Cancer Society (Stanford Cancer Institute/American Cancer Society Pilot Award)
- License Information
-
More Information
Article History
Received: 14 April 2023
Revised: 15 September 2023
Accepted: 29 September 2023
First Online: 13 October 2023
Competing interests
: SS: Research Funding: Magenta Therapeutics, BMS, Allogene, Janssen. Consultancy: Magenta Therapeutics, BMS, Janssen, Sanofi, Oncopeptides, Takeda.
